GRAIL, Inc. (GRAL) Operating Margin
- Operating margin · 12 months: Value -338.40%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -338.40% | Operating income / revenue. Period ending 2026-06-30. $-559.25M ÷ $165.26M × 100 ≈ -338.40% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -559.25M USD | Operating Income (Loss) |
| Revenue | 165.26M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 190.99M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-559.25M | $165.26M | (m) | $190.99M | (m) | -338.40% |
| 2026-03-31 | $-544.32M | $156.12M | (m) | $190.19M | (m) | -348.66% |
| 2025-12-31 | $-562.16M | $147.17M | (m) | $195.79M | (m) | -381.98% |
| 2025-09-30 | $-574.69M | $141.83M | (m) | $197.23M | (m) | -405.20% |
| 2025-06-30 | $-632.91M | $134.28M | (m) | $226.81M | (m) | -471.32% |
| 2025-03-31 | $-2.12B | $130.71M | (m) | $274.38M | (m) | -1618.34% |
| 2024-12-31 | $-2.19B | $125.59M | (m) | $322.38M | (m) | -1743.03% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-1.52B | $93.11M | (m) | $338.75M | (m) | -1627.61% |
| 2023-10-01 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-01-01 | $-5.44B | $55.55M | (m) | $329.58M | (m) | -9798.18% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |